NEWSROOM
DR. SCHOLL'S® Custom Fit™ Orthotic Inserts Now Available in Stores Nationwide |
Revolutionary FootMapping® Technology provides customized comfort and support for people with tired, achy feet |
WHITEHOUSE STATION, NJ, July 13, 2010 – Merck Consumer Care, a subsidiary of Merck & Co., Inc., announces the nationwide availability of Dr. Scholl’s® Custom Fit Orthotic Centers. To help people find customized solutions for their tired, achy feet, the kiosks use revolutionary FootMapping® Technology to measure arch type and the areas you put the most pressure on to recommend the most appropriate Custom Fit™ Orthotic. The FootMapping® Technology found in Dr. Scholl’s® Custom Fit Orthotic Centers was developed by Dr. Scholl’s® scientists and evaluated in five clinical studies. It uses more than 2,000 pressure sensors to measure areas of the foot where the most pressure is applied, arch type and foot length. Based on these criteria, the technology recommends the Dr. Scholl’s® Custom Fit™ Orthotic that’s best for your feet, which provides all-day relief of tired, achy feet and eliminates foot discomfort immediately. “Fifty percent of adults suffer from tired, achy feet, especially if they have jobs that keep them on their feet all day,” said Dr. Leslie Campbell, podiatrist at the Plano Physician’s Group in Plano, Texas and a consultant to the makers of Dr. Scholl’s®. “A customized solution can make a real difference in foot comfort, and these revolutionary Dr. Scholl’s® Custom Fit™ Orthotic Inserts are a great, affordable way for people to relieve their tired, achy feet.” About Dr. Scholl’s® About Merck Consumer Care Forward-Looking Statement The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2009 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). |
| # # # |